# Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean

> **NCT04218162** · PHASE3 · COMPLETED · sponsor: **IlDong Pharmaceutical Co Ltd** · enrollment: 294 (actual)

## Conditions studied

- Acute Migraine

## Interventions

- **DRUG:** Lasmiditan 50mg
- **DRUG:** Lasmiditan 100mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04218162
- **Lead sponsor:** IlDong Pharmaceutical Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-24
- **Primary completion:** 2020-10-30
- **Final completion:** 2020-10-30
- **Target enrollment:** 294 (ACTUAL)
- **Last updated:** 2021-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04218162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04218162, "Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04218162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*